• Filter By:
• Specialty
• Source
• Condition
• Cancer
• Infectious Disease
• Drug
• Training
• Management
• Procedure
• Therapy
• Vaccine
• Nutrition
• Country

New Data From Two Large Studies Reinforce Effectiveness of Dual Pathway Inhibition (DPI) with XARELTO ® (rivaroxaban) Plus Aspirin in Patients with Coronary Artery Disease (CAD) and/or Peripheral Artery Disease (PAD)
RARITAN, N.J., May 23, 2022 – Findings from the XARELTO® (rivaroxaban) Phase 3 COMPASS Long-Term Open Label Extension (LTOLE) study and the XARELTO® in Combination with Acetylsalicylic Acid (XATOA) registry have been published in the European Society of Cardiology’s (ESC) European Heart Journal, Cardiovascular Pharmacotherapy. Additionally, the XATOA registry was presented at the American Congress of Cardiology’s 71st Annual Scientific Session (ACC.22). These studies provide further evidence supporting the role of dual pathway inhibition (DPI) with the XARELTO® vascular dose (2.5 mg twice daily plus aspirin 100 mg...
Source: Johnson and Johnson - May 23, 2022 Category: Pharmaceuticals Source Type: news

Treating and managing diabetic neuropathic foot ulcers
  A study by the Centers for Disease Control and Prevention reports that diabetes rates are at a steady growth, with more than 100 million people in the country living with diabetes or prediabetes as of 2017. This condition has a major impact on overall health and wellness and can cause serious complications involving vision loss, heart disease, stroke, and even toe, foot or leg amputation due to ulcers. Defining diabetic foot ulcers According to the American Podiatric Medical Association, a diabetic foot ulcer is an open wound or sore that occurs in those who have diabetes. Diabetic patients are more likely to develo...
Source: Advanced Tissue - July 1, 2019 Category: Dermatology Authors: AdvancedTissue Tags: Wound Care diabetic foot ulcers Source Type: news